All News

Early Activity With Ibrutinib/Venetoclax Hints New Option in R/R Follicular Lymphoma

January 20, 2021

Ibrutinib in combination with venetoclax displayed preliminary anti-tumor activity along with a tolerable toxicity profile as treatment of patients with relapsed or refractory follicular lymphoma, showing promise for the first-ever Bruton’s tyrosine kinase and BCL-2 inhibitor combination to be explored in the clinical trial setting for this patient population.

FDA Grants Priority Review to 1L Nivolumab Combination in Gastric/GEJ/Esophageal Cancers

January 20, 2021

The FDA has granted a Priority Review to the combination of nivolumab with fluoropyrimidine- and platinum-containing chemotherapy, which is a potential treatment option for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

FDA Grants Priority Review to Adjuvant Nivolumab for Resected Esophageal/GEJ Cancer

January 20, 2021

The FDA accepted a supplemental Biologics License Application for nivolumab as adjuvant treatment of patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiation therapy and granted it Priority Review.

Trastuzumab Deruxtecan Brings HER2 Targeted Therapy to 3L HER2+ Advanced Gastric/GEJ Cancers

January 18, 2021

In an interview with Targeted Oncology, Yelena Y. Janjigian, MD, provided important highlights from the DESTINY-Gastric01 trial and explained the overall impact of the FDA approval of trastuzumab deruxtecan for oncologists treating patients with HER2-positive advanced gastric cancer or GEJ cancers.